Deuterium Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Deuterium Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.69M	Buy	+100,000	New	+$1.4M	1.83%	13

Other funds holding NTLA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

CIC

Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Deuterium Capital Management's NTLA Position: Q2 2026 in Review

Deuterium Capital Management opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 100,000 shares worth $1.69M. The stake represents 1.83% of the portfolio and ranks #13 among its holdings.

130 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Deuterium Capital Management held 100,000 shares of Intellia Therapeutics worth $1.69M as of Q2 2026.
Intellia Therapeutics was a new Deuterium Capital Management position in Q2 2026.
Intellia Therapeutics made up 1.83% of Deuterium Capital Management's portfolio in Q2 2026, its #13 holding.
130 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Deuterium Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.